Brought to you by 
CardioMind gets rights to SurModics' Encore technology
16 Aug 2005
Executive Summary
SurModics (drug delivery, cell encapsulation, and diagnostics) has granted CardioMind (minimally invasive cardiovascular devices) a license to use its Encore drug delivery polymer matrix with the latter's ultra low-profile stent system for coronary and peripheral artery disease.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Biomaterials
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CardioMind gets rights to SurModics' Encore technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice